10,563 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Entropy Technologies LP

Entropy Technologies LP bought a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 10,563 shares of the life sciences company's stock, valued at approximately $1,378,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Illumina by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company's stock valued at $2,505,409,000 after purchasing an additional 66,528 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Illumina by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company's stock valued at $317,267,000 after buying an additional 204,043 shares in the last quarter. Capital World Investors increased its stake in Illumina by 41.1% in the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company's stock valued at $378,111,000 after buying an additional 801,814 shares during the period. Primecap Management Co. CA raised its holdings in shares of Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company's stock worth $253,514,000 after acquiring an additional 1,997,010 shares in the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd raised its position in Illumina by 1.1% during the first quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company's stock valued at $284,097,000 after acquiring an additional 22,067 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

NASDAQ:ILMN traded down $3.93 during trading hours on Thursday, hitting $142.24. The stock had a trading volume of 2,262,878 shares, compared to its average volume of 2,007,583. The firm has a market capitalization of $22.56 billion, a price-to-earnings ratio of -14.68 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a 50 day simple moving average of $139.20 and a two-hundred day simple moving average of $124.10. Illumina, Inc. has a one year low of $92.69 and a one year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the firm posted $0.33 earnings per share. Illumina's quarterly revenue was down 3.5% on a year-over-year basis. Research analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research note on Tuesday. Barclays raised their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Argus upgraded Illumina from a "hold" rating to a "buy" rating and set a $150.00 price objective for the company in a research report on Wednesday, August 28th. Finally, UBS Group increased their price target on shares of Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.